Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 4/20 | 0.42 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3403008 | 0.89 | SNCA (0.43) | SNCANR1D1MAPTALDH1A1 | |
| SCHEMBL3765002 | 0.85 | SNCA (0.46) | SNCAALDH1A1 | |
| SCHEMBL27848293 | 0.85 | SNCA (0.41) | SNCANR1D1MAPTALDH1A1 | |
| SCHEMBL3402058 | 0.81 | SLC6A4 (0.37) | — | |
| SCHEMBL3815723 | 0.78 | MAPT (0.39) | MAPTALDH1A1 | |
| SCHEMBL12330698 | 0.77 | ALDH1A1 (0.42) | NR1D1CYP1A2ALDH1A1 | |
| SCHEMBL5191594 | 0.76 | SNCA (0.49) | SNCANR1D1MAPTALDH1A1 | |
| SCHEMBL16397397 | 0.76 | MAPT (0.44) | NR1D1MAPTCYP1A2ALDH1A1 | |
| SCHEMBL2897902 | 0.76 | HDAC3 (0.46) | NR1D1MAPTALDH1A1 | |
| SCHEMBL17957736 | 0.75 | VCAM1 (0.46) | MAPTCYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250157-B1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LTD (IN) | 2014-11-05 | — | — | EP | disclosed |
| US-8455479-B2 | Heterocyclic compounds | PANACEA BIOTEC LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| CN-101925586-A | Novel heterocyclic compounds | PANACEA BIOTEC LTD | 2010-12-22 | — | — | CN | disclosed |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| EP-2250157-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Panacea Biotec Limited (IN) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009093269-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LIMITED (IN) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DPP4, DPP3, DPP8 | SNCA 4004/4885NR1D1 743/4885MAPT 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.